Samuel Levy

Imagine swallowing the competition whole. That's what many players in tech do via roll-up strategies, gobbling up smaller firms to deliver richer solutions and amass greater market share. Where else are roll-up strategies common? // HEALTHCARE Picture being a patient at a medical practice that’s been part of a roll-up in Healthcare Services. It's an industry ripe for roll-ups due to its fragmented nature and potential for greater efficiency. // CONSUMER SERVICES Or let's say you needed your HVAC serviced, and notice your local repairman is now part of a bigger Consumer Services entity? Centralized management and scale economy turn these localized businesses into roll-up targets. // FINANCIAL SERVICES Think about your insurance agent or wealth management advisor. They're working in complex, highly regulated environments. In the Financial Services sector, roll-ups offer an effective way to consolidate expertise, streamline operations, and enhance customer offerings. // MANUFACTURING Now, imagine driving past factories under a new name — the result of Manufacturing and Industrial Services roll-ups. Bulk purchasing reduces costs, enhances production capabilities, and expands geographical footprints. // REAL ESTATE Lastly, envision your real estate brokerage firm. The industry sees roll-ups as a strategic move to increase market penetration, enhance service offerings, and hike up portfolio value. Roll-ups play a huge role in most industries, rather like a snowball rolling downhill, gaining momentum, and size. Are you seeing roll-ups in your sector or considering M&A?

11

1 commentaire

Thinking about using ePRO in France for older Oncology patients? You might hit some speed bumps. 🛑 "Conclusion Our multicenter study showed a limited feasibility rate (26%) of remote ePROs monitoring for older patients with cancer, mainly because of technology barriers. Yet, among the patients who did have Internet access, most of them indeed used ePROs (66%). " 👀 The only thing I can bring to ePRO's defense is that this hospital group probably didn't consider offline data capture for ePRO, but there are other barriers as well. Just shows once again the answer isnt <<always>> ePRO. But it usually is :). PS. This was done in a care setting, but I think that translates well into research. https://lnkd.in/euxNUWp8

16

2 commentaires

3 noteworthy acquisitions were announced in #DigitalHealth last week, moving the total to 76 acquisitions in 2024 till date. - On Tuesday, Switzerland-based Mediktor announced the acquisition of Sensely, a San Francisco-based digital healthcare provider that pioneered an empathy-driven conversation platform to support hospital systems and insurance services with world-class member engagement. - On Thursday, Carevīve was acquired by Health Catalyst. The acquisition strengthens Health Catalyst's position in the digital healthcare market, expanding its capabilities in patient engagement and care coordination. - On Friday, Doktor.se announced that it acquired competitor Doktor24. The combined entity will provide a comprehensive suite of digital healthcare services, including telemedicine consultations, patient engagement platforms, and data analytics capabilities. Compared to last year, the total number of acquisitions is still trending significantly lower. Till date, the M&A activity in Digital Health has been 14% lower as compared to the same period last year. #Merger #Acquisitions #healthcarefinancing Source: All data from Alpha Edge, the business intelligence tool in HealthTech Alpha

18

1 commentaire

Check out what Peter Stavros, Partner and Co-Head of Global Private Equity at KKR, is up to ! He's championing employee ownership to supercharge performance, and this is a virtuous and highly relevant approach for healthcare! Private Equity (PE) firms like KKR acquire companies with the aim of expanding their size, profitability, and overall value, ultimately selling them for substantial gains and returning profits to investors. Recognizing that engaged employees are crucial to achieving these outsized returns, Pete Stavros has implemented employee ownership programs. These initiatives grant employees free shares, aligning their interests with those of the powerful PE firms. By transforming employees into owners, the goal is to unleash their creativity, energy, and drive towards creating value. Frontline employees often possess invaluable insights into improving processes and boosting productivity, making their engagement pivotal to economical performance and value creation. In a recent CBS 60 MINUTES broadcast, Peter Stavros showcases how this approach fosters a win-win dynamic between PE owners and employee contributors. One compelling example highlighted in the TV show illustrates the tangible impact of employee ownership: when KKR sold a company featured in the documentary, employees received bonuses equivalent to up to 6,5 times their annual salary ! This windfall proved to be life-changing for many employees and families, serving as a powerful motivator to maintain their high performance levels. With Private Equity increasingly involved in the healthcare sector, I'm hopeful that initiatives like this will become more prevalent, providing much-needed motivation in our field. Link to the TV broadcast in the comments below. #PE #PrivateEquity #Employee #Ownership #Value #Healthcare Illustration : TED Conferences

6

1 commentaire

We're witnessing the next wave of leading companies being within healthcare services & being more "involved" than just writing good code. 🌊 I fundamentally believe it's equally important, understanding on the highest granularity, how healthcare is delivered at the core (in the clinics, hospitals & with doctors). A couple years ago there was a massive focus on digital health, this has shifted to healthcare services, experiencing exponential growth atm, due to the following. 📈 1. Operating within the very heterogenous market of healthcare (in particular primary care) requires to understand and interpret operational nuances (those closest to the problem/market will win) and solve for those very operational topics 🩸 2. Pain to innovate is highest amongst those delivering care, as there is no "continuing as before" (patients jump between services/providers based on availability, that's why digital health only takes off v slowly), doctors can't transition away but are "stuck" with their daily operational problems 😵‍💫 3. Willingness to pay is present, (see point 2.) and doctors can afford to pay for these services (shift from paying for "non-available" staff to software) and lastly it's the largest market (DACH €+550B primary care spend) with everyone being a user at one point, opening up multiple cross revenue streams 💸 4. No payor/insurance fights but a "simple" B2B customer (non of the DTx/reimbursement complexities) and a market with unparalleled retention rates (check CompuGroup revenues over the past 10 years, €1.2B in 2023) ⚔️ 5. Less regulation and increasing emphasis/relaxation on data usage (check Patient Data Protection Act or European Health Data Space) as well as enforced digitalisation throughout the upcoming years (every restaurant needs a modern POS, whilst doctors can still operate pen & paper...) ⚖️ Personally I am very bullish, that within the next 5 years, we'll see the N26/Revolut transformation happening in European healthcare - no flying cars - just better operations, services & experiences on top of existing core medical services. 💯 Thanks for the Eterno Health mention Thomas Hagemeijer - V cool overview! 🙌🏽

46

5 commentaires

Interview of David Benshoof Klein, CEO Click Therapeutics, Inc. by Marc Sluijs at Tech Tour's Mental and Brain Health event We create, discover, develop PDTx, 160 people, currently in the US, expanding into Asia and Europe. How does Click look at patient-centricity? There has been a move in that direction in pharma. I thought pharma would love DTx straightaway. They didn't. But things are moving and we had a lot to learn ourselves. In our first programme you had to answer 40 questions. People just dropped out. Now we are down to 7. Engagement science needs to be a core competency. You have to give back to patients. We created a patient alliance. You have to tell that why they are doing something and what they can get out of it. Timing is key as well. When do you notify someone and how? We learned early on that patients learn to ignore notifications. Well-calibrated SMS on the other hand work. You have a number of major pharma-partnerships. How did that happen? We are more structured like a biotech company. On our team 40 are in the clinical, 75 in the technology and 10 in the regulatory team. With a partner that is much like them, they can leverage a lot of their existing infrastructure, assets and capabilities. If you look at our clinical trials, they are very robust and target the same endpoints that a drug trial would target, using very strong controls (that control for time on task etc.). You said that pharma will become obsolete if it does not become digital. How do you see DTx and drugs coming together? We have seen new FDA guidance recently. Should a software show that a drug delivers better outcomes in combination with that software that can get it's own approval. This could prevent loss of exclusivity. We will see a digitalisation of drug portfolios. It might not be as quick as I think, but it will happen. Many drugs will be developed with a companion app attached to it. You can call providers and ask them if adding a certain outcome would affect their prescribing behaviour to understand the impact.

26

🔊 Latest article! 💡 Changing the paradigm of drug discovery processes with AI 💡 We had the privilege of speaking to Cellarity’s CEO, Fabrice Chouraqui, about how the company is leveraging AI to completely revolutionise the drug discovery process and unlock treatments for a vast array of diseases, even in the absence of known targets. Click the link in the comments to read more! 👇 #drugdiscovery #drugtargets #AI

6

1 commentaire

Sharing our thoughts on these two healthcare markets and themes we are actively investing in.

3

Sometimes, the best way to describe what Caresyntax does is through real results. We don't just talk about optimizing healthcare – we deliver. This case study dives deep into how we partnered with a Southeastern health system to optimize their complex ventral hernia repair program. The results are staggering: - Annual cost reduction of $700,000 - Service line net margin improvement of $15,000 per patient - 54% decrease in post-surgical opioid use (safer, happier patients) - 33% reduction in length of stay (patients recover faster) Here's the secret sauce: We go beyond traditional data analysis. Our unique approach connects all the dots – patient factors, treatment details, costs, and reimbursements. This allows us to identify hidden opportunities for improvement. Read this case study to see how we did it. https://lnkd.in/gtebkRU7 #DataDrivenSurgery

88

4 commentaires

French Company Pioneers Artificial Intelligence for Brain Targeting RebrAIn #parkinson #essentialtremor #DBS #HIFU #artificialintellingence Focused Ultrasound Foundation Emmanuel Cuny Nejib Zemzemi Karista MCAPITAL RebrAIn pairs artificial intelligence with health data to simplify and standardize targeting for neurological procedures.  Learn how the technology works for surgical interventions and how the company plans to apply it to focused ultrasound treatment https://lnkd.in/ex6YuFCZ

74

4 commentaires

HITLAB is pleased to announce its 7th session of the HITLAB Virtual Knowledge Share featuring Laurent van Lerberghe, Investor Digital Health at ballas invest. Laurent will be presenting on the topic of "New Possibilities to Manage Health from Birth to Quality Aging." This informative session will explore cutting-edge advancements in health management, empowering you to take charge of your well-being at every stage of life. Some key topics that will be addressed include: - Proactive health strategies: Learn preventative measures to optimize your health throughout your life.  - Emerging technologies: Explore how advancements in medicine and technology are revolutionizing health management.  - Living a life of quality aging: Gain insights on fostering vitality and well-being as you age. Why You Should Attend:  - Expert Insights: Learn from Laurent Van-Lerberghe, a leading expert in health investment and management.  - Cutting-Edge Knowledge: Discover the latest innovations and strategies in health management from birth to aging.  - Interactive Q&A: Engage directly with Laurent during the Q&A session to get your pressing questions answered. - Networking Opportunities: Connect with other professionals in the health tech industry. Don’t miss this unique opportunity to enhance your understanding and management of health across all life stages. Register now to secure your spot and be part of a community that is at the forefront of healthcare innovation! Want to join? Become a BT1 member today: https://lnkd.in/e6N2q7UT #HITLAB #HealthTech #VirtualKnowledgeShare #HealthcareInnovation #QualityAging #Wellbeing #HealthManagement #DigitalHealth #FutureOfHealthcare #breakthrough

8

One key reason why healthcare technologies like AI, telemedicine, and software haven't structurally lowered costs or broadened access for the entire system after decades of experimentation (excluding pure financial engineering of payer contracts) is the limited reimagining of care delivery itself, with asynchronous telemedicine as a notable exception. In the same way that digitizing physical paper failed to exploit the capabilities of a new computing medium for word processing, hosting physician-patient conversations over video does not transform the actual delivery of care. In telemedicine, many of the inputs (e.g., clinician time) and therefore cost structures of in-person care persist, which is why we often see fee-for-service telemedicine companies struggle to achieve economies of scale (i.e., growing revenues non-linearly while growing costs linearly). Until we deconstruct the components of a medical appointment – from intake and triage, to chart review, history gathering, physical examination, diagnosis, treatment, and follow-up – we will continue to be underwhelmed by the disconnect between the transformative potential of these technologies and real-world patient/system impact. I’m optimistic that the emergence of reliable and performant medical AI agents will urge us to perform this deconstruction and redesign the fundamental building blocks of a “medical appointment.”

215

39 commentaires

📈🌍 Digital Health Funding Surges in H1 2024: Investor Confidence Rebounds The latest data from the Galen Growth | Insights You Can Trust H1 2024 report, a comprehensive 80+ page analysis filled with data, charts, and unrivalled insights, indicates a resurgence in #venturecapital inflows into the #DigitalHealth sector. This analysis reveals that #ecosystem funding stress is beginning to ease, particularly in the #US, where the proportion of Growth Stage ventures securing #funding has risen by 2% QoQ over the past 18 months, aligning with #Europe steady 42% at the end of H1. Digital Health ventures globally are seeing renewed #investor confidence, with venture capital deployment surpassing H1 2023 values. Galen Growth’s #AlphaForecaster predicts that ventures with above-average #signals will attract significant investor interest in the latter half of 2024. The easing of funding stress in the US is evident, as the share of Growth Stage ventures #raising capital has increased consistently over the past three quarters. #Europe continues its steady performance, but with nearly half of all Late-Stage ventures having raised funding in the past 18 months, the focus now shifts to the remaining ventures needing capital in the coming months. Despite indications of a quieter period for deal activity, investor interest remains strong. Download (FOC) the full report for more detailed insights and data.

30

2 commentaires

🔊 Weekly round-up! 💡 Changing the paradigm of drug discovery processes with AI We had the privilege of speaking to Cellarity’s CEO, Fabrice Chouraqui, about how the company is leveraging AI to completely revolutionise the drug discovery process and unlock treatments for a vast array of diseases, even in the absence of known targets.   💻 Part one: what can scientists do with LLMs today? In the first of a three-part series, Dr Raminderpal Singh explores what LLMs are, how early stage biotechs can take advantage of them, and what challenges they present. 💊Novel inhibitor developed to combat HER2-positive breast cancer Researchers at Korea University have developed an inhibitor named HVH-2930, which effectively induced apoptosis in breast cancer cells without initiating the heat shock response. 🧫Elucidating the loss of mobility caused by LGMD2B Biomedical engineers at Duke University grew complex, functional 3D muscle tissue from stem cells to study limb girdle muscular dystrophies 2B (LGMD2B). This enabled the biological mechanisms underlying the loss of mobility caused by LGMD2B to be elucidated. Click on the links in the comments to read more! 👇 #drugdiscovery #lifescience #drugtargets 

9

1 commentaire

Thank you Henry Peck and Scott Pantel for this great piece by Henry on how common practices in venture apply to digital health investing. In VC we say it's all about the founders, but honestly in healthcare, a great team is critical but is only one ingredient in the recipe to success. Choosing markets vs founders is not necessary. As investors looking for outliers, we must prioritize both. It is the best markets where you can build an amazing company. It is the best founders who can find a wedge and the next business opportunity and identify where and when to grow and how to shorten sales cycles and tap into buyers' priorities. In between these two factors, in digital health, we also have regulation, reimbursement, compliance, IP and all these other fun stuff that may change time to market but will be cracked by the best teams in great markets. Enjoy the read! https://lnkd.in/d6euMfeB

18

1 commentaire

"“The detection of AFib significantly improved over the past two decades, primarily due to advancements in technology, changes in clinical practice and increased awareness,” the authors wrote. “Approximately a third of patients with AFib are asymptomatic, and enhanced detection over time may lead to increased lifetime risk of diagnosed AFib. Another possible reason is the global increase in life expectancy.” Meanwhile, AFib patients faced high lifetime risks of developing heart failure (41%) or experiencing a stroke (21%). The lifetime risk of an AFib patient suffering a myocardial infarction was 12%. “Our findings encourage greater attention to secondary prevention of heart failure after AFib, and in line with a recent report from the National Heart, Lung, and Blood Institute, relevant future initiatives include development of non-anticoagulant pharmacotherapies, effective implementation of weight loss and risk factor modification, and designing successful programs for cardiac rehabilitation. As AFib is a common arrhythmia, a lower incidence of complications may reduce the future economic costs in healthcare.”" MedTech Innovator American Heart Association Heart Rhythm Society American College of Cardiology #epeeps LSI

44

2 commentaires

How does AI help medical inventions? 🤝 Interviewed by the L'Obs Newspaper during the #Vivatech conference in #Paris, the president and founder of Withings, Mr. Eric CARREEL stated: 𝘼 𝙣𝙚𝙬 𝙢𝙚𝙙𝙞𝙘𝙞𝙣𝙚 𝙞𝙨 𝙗𝙚𝙞𝙣𝙜 𝙞𝙣𝙫𝙚𝙣𝙩𝙚𝙙, 𝙡𝙞𝙣𝙠𝙚𝙙 𝙩𝙤 𝙩𝙝𝙚 𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙤𝙛 𝘼𝙄. 𝙏𝙤𝙙𝙖𝙮, 𝙬𝙚 𝙖𝙧𝙚 𝙖𝙗𝙡𝙚 𝙩𝙤 𝙘𝙤𝙡𝙡𝙚𝙘𝙩 𝙙𝙖𝙩𝙖 𝙬𝙝𝙞𝙘𝙝 𝙦𝙪𝙖𝙣𝙩𝙞𝙩𝙮 𝙪𝙡𝙩𝙞𝙢𝙖𝙩𝙚𝙡𝙮 𝙥𝙧𝙤𝙫𝙞𝙙𝙚𝙨 𝙢𝙪𝙘𝙝 𝙢𝙤𝙧𝙚 𝙞𝙣𝙛𝙤𝙧𝙢𝙖𝙩𝙞𝙤𝙣: 𝙮𝙤𝙪 𝙘𝙖𝙣 𝙛𝙤𝙡𝙡𝙤𝙬 𝙩𝙝𝙚 𝙚𝙫𝙤𝙡𝙪𝙩𝙞𝙤𝙣 𝙤𝙛 𝙩𝙝𝙚 𝙥𝙚𝙧𝙨𝙤𝙣 𝙤𝙫𝙚𝙧 𝙖 𝙡𝙤𝙣𝙜 𝙩𝙞𝙢𝙚 𝙖𝙣𝙙 𝙨𝙚𝙚 𝙩𝙝𝙖𝙩 𝙩𝙝𝙚𝙧𝙚 𝙞𝙨 𝙨𝙤𝙢𝙚𝙩𝙝𝙞𝙣𝙜 𝙙𝙚𝙩𝙚𝙧𝙞𝙤𝙧𝙖𝙩𝙞𝙣𝙜 𝙖𝙣𝙙 𝙨𝙤𝙪𝙣𝙙 𝙩𝙝𝙚 𝙖𝙡𝙖𝙧𝙢 𝙗𝙮 𝙞𝙣𝙫𝙞𝙩𝙞𝙣𝙜 𝙝𝙞𝙢 𝙩𝙤 𝙘𝙤𝙣𝙨𝙪𝙡𝙩. 𝙏𝙝𝙞𝙨 𝙞𝙨 𝙩𝙝𝙚 𝙢𝙚𝙙𝙞𝙘𝙞𝙣𝙚 𝙩𝙝𝙖𝙩 𝙬𝙚 𝙞𝙢𝙖𝙜𝙞𝙣𝙚 𝙛𝙤𝙧 𝙩𝙤𝙢𝙤𝙧𝙧𝙤𝙬. Withings is known for its innovative health technology products like smart scales, activity trackers, smartwatches, blood pressure monitors, and sleep-tracking devices. This time, Mr. Carreel shares his vision for the future of medicine. Read the whole interview here: https://lnkd.in/eeXVH4z8 ✨ #Withings and @Inviggo have been partners for two years. ✉ If you need a tech team to support your project, contact us to estimate your needs together: office@inviggo.com. #inviggo #MedTech #DigitalHealth #TeleHealth #ArtificialIntelligence

2

Big healthcare AI news yesterday as Tempus AI received the first-ever CPT code for an algorithm-only analysis of previously-sequenced, laboratory developed test transcriptomic data. TLDR: AI molecular phenotyping has a new business model. The PurISTSM test uses RNA profiling to identify molecular subtypes in patients with advanced pancreatic ductal adenocarcinoma, which may inform first-line therapy selection and management. While I'm skeptical that payer balance sheets are going to solve the "who pays for healthcare AI" problem, the reimbursement pipes for clinical AI are maturing. I am surprised to see more progress for usage-based vs. performance-based models given the many challenges with FFS economics. It will be interesting to see how payers assess the "medical necessity" and therefore reimbursability of clinical AI as these models come to market. https://t.co/eLe18SmihV

420

8 commentaires

Unlock your full clinical productivity potential by combining DAX Copilot with Dragon Medical One. Learn more at https://lnkd.in/e86xfcb7

1